loader
Home
Suh-Chin Wu

EDITORIAL BOARD MEMBER - Suh-Chin Wu


Suh-Chin Wu

Department of Medical Science
National Tsing Hua University
Taiwan

BIOGRAPHY:

Dr. Suh-Chin Wu is Professor of Institute of Biotechnology, Department of Medical Science at National Tsing Hua University, Hsinchu, Taiwan. He is currently the Adjunct Investigator of National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan. He received his Ph.D. in Chemical Engineering from Texas A&M University, completed his postdoctoral training at NCBI/NCI-Frederick, National Institute of Health, US. He joined the vaccine group at Taiwanese Center of Disease Control as Associate Investigator and then moved to the Department of Life Science, National Tsing Hua University, Taiwan. He has participated with the Taiwanese CDC/NHRI vaccine group(s) in the developments of inactivated cell culture vaccines for Japanese encephalitis, enterovirus type 71, H5N1, and pH1N1 viruses. His current works are focused on the novel antigen and adjuvant design for inducing more potent neutralizing antibodies, mucosal IgA antibodies, and Th17 cellular response against virus infections. For human and avian influenza vaccine research, the rationale design for "glycan-masking" and "glycan-unmasking" HA antigens is used to elicit more broadly neutralizing antibodies by refocusing the antibody responses to the more conserved regions. Another approach is to dissect the cross-reactive epitopes on the NA antigens for inducing more cross-reactive NA inhibiting antibodies that may also improve vaccine protection or the outcome of disease severity. For dengue and Zika vaccine research, his works include the use of infectious clone technology to construct mutant viruses for developing live-attenuated vaccines. He has authored over 80 scientific papers and 10 patents related to human vaccine and biologics development. He has also co-founded the Taiwan Chapter of Regulatory Affairs Professionals Society (RAPS) for promoting the education in regulatory sciences for biologics and vaccines, and is currently the chairman of RAPS Taiwan Chapter.

RESEARCH INTERESTS:

We are interested in the vaccine research for the currently emerging viral diseases of dengue, Zika, and human/avian influenza pH1N1, H3N2, H5N1and H7N9 viruses. Our approaches are mostly based on the novel antigen and adjuvant design to elict more potent neutralizing antibodies, mucosal IgA antibodies, and Th17 cellulare immunity agasint virus infections. For human and avian influenza vaccine research, the rationale design for "glycan-masking" and "glycan-unmasking" HA antigens (NTHU Universal Novel Influenza Vaccine) is used to elicit more broadly neutralizing antibodies by refocusing the antibody responses to the more conserved regions. Another apprach is to dissect the cross-reactive epitopes on the NA antigens for inducing more NA inhibiting antibodies that may also improve vaccine protection or the outcome of disease severity. For dengue and Zika vaccine research, we used infectious clone technology to construct mutant viruses for developing live-attenuated vaccines. For CHO cell line development, we have designed a siRNA vector targetting on dhfr gene to obtain high-producer stable cell clones through stepwise MTX selection.